<?xml version="1.0" encoding="UTF-8"?>
<p>CTU level guidance in response to the COVID-19 crisis advocated halting new recruitment and continue to follow-ups in 7/18 units (39%). Eight CTUs (44%) indicated that the trial team (trial managers or chief investigators) should evaluate the risk-benefit of their trial with regards to continuing or halting recruitment. Two units (11%) encouraged continued recruitment where possible. These data are illustrated in FigureÂ 
 <xref ref-type="fig" rid="FIG6">6</xref>.
</p>
